icon-folder.gif   Conference Reports for NATAP  
 
  15th European AIDS Conference (EACS)
October 21-24, 2015
Barcelona
Back grey_arrow_rt.gif
 
 
 
Patient Reported Outcomes Over 48 Weeks in a Randomized, Open-Label Trial of Patients With HIV Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide (E/C/F/TAF)
 
 
  ....Switching off efavirenz from EFV/FTC/TDF to E/C/F/TAF was associated with significant declines in the prevalence of EFV-associated neuropsychiatric symptoms
 
Reported By Jules Levin
EACS 2015 Oct 21-24 Barcelona, Spain
 
Thomas Lutz,1 Paul Benson,2 Jean-Christophe Goffard,3 Richard Haubrich,4 David Budd4
1Infektiologikum, Frankfurt am Main, Germany; 2Be Well Medical Center, Berkeley, Michigan, USA; 3H˘pital Erasme, Brussels, Belgium; 4Gilead Sciences, Inc., Foster City, California, USA

EACS1.gif

EACS2.gif

EACS3.gif

EACS4.gif

EACS5.gif

EACS6.gif

EACS7.gif

EACS8.gif

EACS9.gif

EACS10.gif

EACS11.gif

References
 
1. Al-Dakkak I, et al. AIDS Care 2013;25(4):400-14; 2. Rosenblum M, et al. PLoS One 2009;4(9):e7196; 3. Sweet D, et al. IAS 2014. Abstract THPE421; 4. Edelman EJ, et al. AIDS Behav 2011;15(4):853-61; 5. Mills A, et al. IAS 2015. Abstract TUAB0102; 6. Sustiva [package insert] Princeton, NJ: Bristol-Myers Squibb Pharma Company; 2015; 7. The EuroQol Group. Health Policy 1990;16(3):199-208; 8. Hsiung PC, et al. Qual Life Res 2005;14(1):141-50.